Precision Debt To Assets from 2010 to 2024

DTIL Stock  USD 6.50  0.68  9.47%   
Precision BioSciences Debt To Assets yearly trend continues to be quite stable with very little volatility. Debt To Assets may rise above 0.15 this year. From the period between 2010 and 2024, Precision BioSciences, Debt To Assets regression line of its data series had standard deviation of  0.05 and standard deviation of  0.05. View All Fundamentals
 
Debt To Assets  
First Reported
2010-12-31
Previous Quarter
0.14026699
Current Value
0.15
Quarterly Volatility
0.04875496
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Precision BioSciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Precision BioSciences' main balance sheet or income statement drivers, such as Interest Income of 8.2 M, Interest Expense of 2.3 M or Selling General Administrative of 29 M, as well as many indicators such as Price To Sales Ratio of 0.82, Dividend Yield of 0.0 or PTB Ratio of 2.34. Precision financial statements analysis is a perfect complement when working with Precision BioSciences Valuation or Volatility modules.
  
Check out the analysis of Precision BioSciences Correlation against competitors.
For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.

Latest Precision BioSciences' Debt To Assets Growth Pattern

Below is the plot of the Debt To Assets of Precision BioSciences over the last few years. It is Precision BioSciences' Debt To Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Precision BioSciences' overall financial position and show how it may be relating to other accounts over time.
Debt To Assets10 Years Trend
Slightly volatile
   Debt To Assets   
       Timeline  

Precision Debt To Assets Regression Statistics

Arithmetic Mean0.04
Geometric Mean0.02
Coefficient Of Variation134.06
Mean Deviation0.04
Median0.01
Standard Deviation0.05
Sample Variance0
Range0.1371
R-Value0.71
Mean Square Error0
R-Squared0.50
Significance0
Slope0.01
Total Sum of Squares0.03

Precision Debt To Assets History

2024 0.15
2023 0.14
2022 0.0933
2021 0.0203

About Precision BioSciences Financial Statements

Precision BioSciences investors utilize fundamental indicators, such as Debt To Assets, to predict how Precision Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Debt To Assets 0.14  0.15 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Precision BioSciences is a strong investment it is important to analyze Precision BioSciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Precision BioSciences' future performance. For an informed investment choice regarding Precision Stock, refer to the following important reports:
Check out the analysis of Precision BioSciences Correlation against competitors.
For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precision BioSciences. If investors know Precision will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Precision BioSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.4
Revenue Per Share
12.872
Quarterly Revenue Growth
(0.96)
Return On Assets
(0.06)
Return On Equity
0.2444
The market value of Precision BioSciences is measured differently than its book value, which is the value of Precision that is recorded on the company's balance sheet. Investors also form their own opinion of Precision BioSciences' value that differs from its market value or its book value, called intrinsic value, which is Precision BioSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Precision BioSciences' market value can be influenced by many factors that don't directly affect Precision BioSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Precision BioSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Precision BioSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Precision BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.